Walleye Capital LLC Grows Stock Holdings in Vaxcyte, Inc. $PCVX

Walleye Capital LLC grew its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 242.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 362,610 shares of the company’s stock after acquiring an additional 256,644 shares during the period. Walleye Capital LLC owned about 0.28% of Vaxcyte worth $11,788,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in PCVX. US Bancorp DE raised its position in Vaxcyte by 7.2% in the first quarter. US Bancorp DE now owns 5,344 shares of the company’s stock valued at $202,000 after purchasing an additional 357 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Vaxcyte by 5.8% in the first quarter. PNC Financial Services Group Inc. now owns 9,600 shares of the company’s stock valued at $362,000 after buying an additional 524 shares in the last quarter. Hsbc Holdings PLC raised its holdings in shares of Vaxcyte by 3.1% during the 1st quarter. Hsbc Holdings PLC now owns 18,461 shares of the company’s stock valued at $675,000 after buying an additional 552 shares during the period. J.Safra Asset Management Corp raised its holdings in shares of Vaxcyte by 18.5% during the 2nd quarter. J.Safra Asset Management Corp now owns 3,746 shares of the company’s stock valued at $122,000 after buying an additional 585 shares during the period. Finally, Atria Investments Inc lifted its position in Vaxcyte by 11.1% during the 2nd quarter. Atria Investments Inc now owns 6,816 shares of the company’s stock worth $222,000 after acquiring an additional 683 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the stock. BTIG Research reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Vaxcyte in a research report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday, October 14th. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. Leerink Partners set a $77.00 price objective on shares of Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Finally, The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday, September 12th. They issued a “neutral” rating and a $38.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $97.83.

Vaxcyte Trading Down 3.4%

Shares of NASDAQ:PCVX opened at $46.07 on Friday. The firm has a market cap of $6.03 billion, a PE ratio of -9.52 and a beta of 1.28. The company has a fifty day simple moving average of $43.94 and a 200 day simple moving average of $36.99. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $94.60.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same period in the prior year, the business earned ($0.83) EPS. As a group, equities research analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.